​

New PDUFA goal date for ezogabine in the U.S.

​

Valeant Pharmaceuticals International (Meda’s partner for ezogabine - known as retigabine outside of the U.S.) has announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine by three months to 30 November 2010. Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial onset seizures.

 

 

If questions, please contact: Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

---